Hologic Finalizes Endomagnetics Acquisition

Hologic, a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics, a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million. 

 

The transaction adds Endomagnetic’s wireless breast surgery localization and lymphatic tracing solutions to Hologic’s breast surgery portfolio. This will offer breast surgeons and radiologists an expanded range of options and enhanced user experience.

 

Endomagnetic solutions include the Magseed marker, the Magtrace lymphatic tracer, and the Sentimag platform.

 

“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio,” “With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic.

 

Eric Mayes, PhD, Chief Executive Officer of Endomag, commented, “We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation, and deep engagement with clinicians. As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”